Important note: Guardant Reveal and Guardant360 Liquid were developed as Laboratory Developed Tests (LDT), and their performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. These tests have not been cleared or approved by the US FDA.

ctDNA, circulating tumor DNA; MRD, molecular residual disease; CRC, colorectal cancer. * When compared to other tissue-free testing companies. Comparisons are based on publicly available analytical specification information as of October 2025. † Limit of detection in colorectal cancer (MRD). ‡ Median turnaround time from sample receipt to first results. § Median turnaround time from sample receipt to first results. Comparisons are against other tissue-free testing companies based on publicly available information as of October 2025. ¶ Initiation of follow up molecular profiling with Guardant360 Liquid requires that no Guardant liquid therapy selection test has been performed within the prior 45 days and that other program criteria are met: (1) stage II–III surveillance with a positive Guardant Reveal MRD result and tumor fraction (TF) ≥0.05%; or (2) advanced disease on therapy, a current positive Guardant Reveal result and TF >50% higher than the prior test, and a confirmatory Guardant Health Test Requisition Form (TRF); and (3) other predefined performance thresholds. II Guardant Reveal is covered by Medicare to guide adjuvant therapy decision-making following surgery and for longitudinal recurrence surveillance every 3 to 6 months in CRC.

References: 1. Guardant Reveal Assay Specifications. 2025. Guardant Health, Inc. Redwood City, CA. 2. Nakamura Y, Tsukada Y, Matsuhashi N, et al. Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay. Clin Cancer Res. 2024. 3. Liang SI, Quandt Z, Wienke S, et al. Methylation-based ctDNA tumor fraction changes predict long-term clinical benefit from immune checkpoint inhibitors in RADIOHEAD, a real-world pan-cancer study. Cancer Res Commun. 2025. 4. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014. 5. Dasari A, Morris VK, Allegra CJ, et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. 2020. 6. Yang Y, Lu Y, Tan H, et al. The optimal time of starting adjuvant chemotherapy after curative surgery in patients with colorectal cancer. BMC Cancer. 2023. 7. Courtney D, Davey MG, Moloney BM, et al. Breast cancer recurrence: factors impacting occurrence and survival. Ir J Med Sci. 2022. 8. Elliott MJ, Kim J, Dou A, et al. Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early breast cancer. ESMO Open. 2025. 9. Ademuyiwa FO, Ma CX, Weilbaecher K, et al. Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer. Clin Cancer Res. 2025.